Corvus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company based in Burlingame, California, focused on pioneering immuno-oncology therapies that aim to redefine cancer treatment paradigms. The company is advancing a diverse pipeline of proprietary drug candidates designed to stimulate immune responses and improve patient outcomes through targeted approaches. With a commitment to innovation and strategic collaborations, Corvus is positioning itself as a key contributor in the dynamic oncology market, driving significant advancements that have the potential to transform cancer therapeutics and enhance patient care. Show more

Location: 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080, South San Francisco, CA, 94080, USA | Website: https://www.corvuspharma.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

1.734B

52 Wk Range

$2.54 - $26.95

Previous Close

$20.94

Open

$20.69

Volume

2,425,683

Day Range

$20.20 - $21.71

Enterprise Value

1.689B

Cash

2.867M

Avg Qtr Burn

-9.566M

Insider Ownership

3.52%

Institutional Own.

51.80%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Soquelitinib (CPI-818) Details Peripheral T-cell Lymphomas	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab (CPI-006) Details Cancer, Lung cancer, Renal cell carcinoma, Non-small cell lung carcinoma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib Details Autoimmune Lymphoproliferative Syndrome	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) Details Cancer, Renal cell carcinoma (renal cell cancer)	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Soquelitinib (CPI-818) Details Atopic dermatitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ciforadenant +/- ipilimumab and nivolumab Details Cancer, 1L metastatic renal cell carcinoma (renal cell cancer)	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab + pembrolizumab Details Cancer, Head and neck cancer, Non-small cell lung carcinoma	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Mupadolimab (CPI-0060) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.